Radiochemical studies, pre-clinical investigation and preliminary clinical evaluation of 170 Tm-EDTMP prepared using in-house freeze-dried EDTMP kit

India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate

“…[ 20 ] Colleagues from radiopharmaceuticals chemistry section, radiochemistry, and isotope group, BARC, Mumbai have produced many therapeutic radiolabeled tracers and have shown excellent therapeutic efficacy and are offered to patients throughout the country at an affordable cost. [ 21 , 22 , 23 , 24 , 25 , 26 ]…”

Cutting edge rare earth radiometals: prospects for cancer theranostics

“…Further preclinical work towards the implementation of 170 Tm in bone pain palliation applications has been undertaken by radiolabelling a series of both cyclic and acyclic polyaminophosphonic acid-based chelators, namely EDTMP, diethylenetriaminepentamethylenephosphonic acid (DTPMP), triethylenetetraminehexamethylenephosphonic acid (TTHMP), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP) and 1,4,8,11-tetraazacyclotetradecane-1–4-8–11-tetramethylenephosphonic acid (CTMP) (see Fig. 12 ) (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ). Dosimtery, biodistribution, pharmacokinetic, scinitigraphic and SPECT imaging studies of these radiolabelled compounds have given a preponderance of promising preclinical data indicating the significant potential for 170 Tm as a theranostic probe for bone pain palliation arising from various cancers metastasising to the skeleton (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ).…”

“…12 ) (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ). Dosimtery, biodistribution, pharmacokinetic, scinitigraphic and SPECT imaging studies of these radiolabelled compounds have given a preponderance of promising preclinical data indicating the significant potential for 170 Tm as a theranostic probe for bone pain palliation arising from various cancers metastasising to the skeleton (Vats et al 2013 ; Shirvani-Arani et al 2013 ; Shirmardi et al 2020 ; Das et al 2017 ). In one study, 170 Tm was prepared using a 169 Tm 2 (NO 3 ) 3 target and a neutron flux of 3–4 × 10 13 n/cm 2 /s for 5 days, resulting in a final formulation with adequate specific activity and radiopurity (> 99.99%) suitable for subsequent radiolabelling EDTMP with a yield of > 99% and high in vitro stability (> 95% after two months incubation at RT).…”

“…More recently, however, [ 170 Tm]Tm-EDTMP has attracted more considerable research attention. Further preclinical studies and preliminary clinical investigations have afforded results that are indicative of the significant future potential of [ 170 Tm]Tm-EDTMP as a theranostic agent in bone pain palliation (Shirmardi et al 2020 ; Das et al 2017 ). One illustrative example is the efficacy evaluation of a freeze-dried EDTMP kit for the in-house preparation of [ 170 Tm]Tm-EDTMP which has provided encouraging results (Das et al 2017 ).…”